PPAR-δ, one of the most promising pharmacological target implicated in obesity-associated insulin resistance [7], is highly expressed in skeletal muscle, at 10- and 50-folds higher levels compared with PPAR-α and PPAR-γ, respectively [8]. The gene discussed is PPARD; the disease is obesity due to melanocortin 4 receptor deficiency.